CRISPR Therapeutics AG (NASDAQ:CRSP) was the target of a significant drop in short interest in May. As of May 28th, there was short interest totalling 3,320,000 shares, a drop of 14.2% from the May 13th total of 3,870,000 shares. Approximately 5.3% of the company's stock are sold short. Based on an average trading volume of 1,380,000 shares, the short-interest ratio is presently 2.4 days.
CRSP has been the topic of a number of analyst reports. Citigroup upgraded CRISPR Therapeutics from a "sell" rating to a "neutral" rating and raised their price target for the company from $55.00 to $132.00 in a research note on Monday. Evercore ISI upgraded CRISPR Therapeutics to an "outperform" rating in a research report on Thursday, May 13th. Barclays lifted their target price on CRISPR Therapeutics from $140.00 to $160.00 and gave the stock an "overweight" rating in a research report on Wednesday, April 21st. JMP Securities started coverage on CRISPR Therapeutics in a research report on Thursday, March 4th. They set an "outperform" rating and a $160.00 target price on the stock. Finally, Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell upgraded CRISPR Therapeutics from a "sell" rating to a "neutral" rating and lifted their target price for the stock from $55.00 to $132.00 in a research report on Monday. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating and fourteen have issued a buy rating to the company's stock. The stock has an average rating of "Buy" and a consensus target price of $158.68.
CRSP traded down $0.52 during trading on Friday, reaching $126.75. The company's stock had a trading volume of 29,028 shares, compared to its average volume of 1,861,814. CRISPR Therapeutics has a 52-week low of $65.51 and a 52-week high of $220.20. The firm has a fifty day moving average of $118.38. The company has a market capitalization of $9.60 billion, a P/E ratio of -22.61 and a beta of 2.26.
CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Monday, April 26th. The company reported ($1.51) earnings per share for the quarter, missing the Zacks' consensus estimate of ($1.47) by ($0.04). CRISPR Therapeutics had a negative net margin of 35,630.97% and a negative return on equity of 27.42%. Equities research analysts forecast that CRISPR Therapeutics will post 0.66 EPS for the current fiscal year.
In other CRISPR Therapeutics news, Director Bradley J. Phd Bolzon sold 10,000 shares of the firm's stock in a transaction on Friday, June 11th. The stock was sold at an average price of $126.61, for a total value of $1,266,100.00. Following the sale, the director now directly owns 24,948 shares in the company, valued at $3,158,666.28. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Bradley J. Phd Bolzon sold 30,374 shares of the firm's stock in a transaction on Monday, March 22nd. The shares were sold at an average price of $132.37, for a total value of $4,020,606.38. Following the completion of the sale, the director now owns 57,149 shares in the company, valued at $7,564,813.13. The disclosure for this sale can be found here. Over the last quarter, insiders sold 70,374 shares of company stock worth $9,079,606. Insiders own 17.10% of the company's stock.
A number of institutional investors and hedge funds have recently made changes to their positions in CRSP. Abundance Wealth Counselors purchased a new stake in CRISPR Therapeutics in the 1st quarter valued at approximately $26,000. RMR Wealth Builders purchased a new stake in CRISPR Therapeutics in the 1st quarter valued at approximately $29,000. Ameritas Investment Company LLC purchased a new stake in CRISPR Therapeutics in the 1st quarter valued at approximately $29,000. Eudaimonia Partners LLC purchased a new stake in CRISPR Therapeutics in the 1st quarter valued at approximately $31,000. Finally, Total Clarity Wealth Management Inc. acquired a new stake in shares of CRISPR Therapeutics during the 1st quarter valued at approximately $32,000. 55.60% of the stock is currently owned by institutional investors.
About CRISPR Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA.
Further Reading: Beige Book
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Featured Article: Moving Average - How it Helps Investors in Stock Selection
Who knew that something so tiny could create such a big problem? However, that’s the case with the semiconductor industry. Chip manufacturers are facing supply chain disruptions due to the Covid-19 pandemic.
Semiconductors are in high demand for the big tech companies who need the chips to power the servers for their data centers. But they are also needed for much of the technology we take for granted including laptops, tablets, mobile phones, gaming consoles, and automobiles – a sector that seems to be at the root of the current crisis.
Any weekend mechanic knows that even traditional internal combustion cars are heavily reliant on electronics. In fact, electronic parts and components account for 40% of a new, internal combustion vehicle. That’s more than doubled since 2000.
However as it turns out, some manufacturers may have overestimated how soon consumers would be ready for an “all-electric” future. And that meant that they didn’t forecast how much demand there would be for the kind of chips needed to do the mundane, but vital tasks of steering, braking, and even powering windows up and down.
Part of the problem is that U.S. businesses are heavily reliant on countries like China and Taiwan for their semiconductors. In fact, only about 12.5% of semiconductor manufacturing is done in the United States.
Of course, this creates a tremendous opportunity for the companies that manufacture these chips. And it comes at a good time. The semiconductor sector is notoriously cyclical and was coming down from the elevated demand for the 5G buildout.
In this special presentation, we’ll give you a list of seven semiconductor companies that you can invest in to take advantage of this opportunity.